Allscripts Announces Third Quarter 2012 Results

               Allscripts Announces Third Quarter 2012 Results

Company Evaluating Strategic Alternatives

PR Newswire

CHICAGO, Nov. 8, 2012

CHICAGO, Nov. 8, 2012 /PRNewswire/ --Allscripts Healthcare Solutions, Inc.
(NASDAQ: MDRX) today announced the following financial results for the three
and nine months ended September 30, 2012.

Third Quarter Details:

  oBookings(1)  of $161.9 million. This compares with bookings of $266.8
    million in the third quarter of 2011 and $194.1 million in the second
    quarter of 2012.
  oGAAP revenue of $360.7 million and non-GAAP revenue of $361.0 million.
    This compares with GAAP and non-GAAP revenue of $363.7 and $366.3 million,
    respectively, in the third quarter of 2011.
  oGAAP gross profit for the three months ended September 30, 2012, was
    $157.0 million. This compares with GAAP gross profit of $162.0 million in
    the third quarter of 2011.
  oNon-GAAP gross profit was $157.3 million for the three months ended
    September 30, 2012, or 43.6 percent of total non-GAAP revenue. This
    compares with $164.6 million or 44.9 percent of non-GAAP revenue for the
    prior year.
  oGAAP operating income for the three months ended September 30, 2012, was
    $9.2 million. This compares with GAAP operating income of $34.4 million
    in the third quarter of 2011.
  oNon-GAAP operating income was $50.0 million for three months ended
    September 30, 2012, or 13.8 percent of total non-GAAP revenue. This
    compares with $72.3 million or 19.7 percent of non-GAAP revenue for the
    prior year.
  oGAAP net income for the three months ended September 30, 2012 was $9.4
    million and GAAP diluted earnings per share was $0.05. This compares with
    $19.1 million and $0.10, respectively, in the third quarter of 2011.
  oThird quarter 2012 GAAP results include the following items, all on a
    pre-tax basis:

       oDeferred revenue adjustment of $0.3 million, acquisition-related
         amortization expense of $15.7 million, stock-based compensation
         expense of $8.8 million and transaction-related and non-recurring
         expenses totaling $4.9 million.
       oAn $11.1 million non-cash asset impairment charge associated with the
         Company's previously announced plan to standardize its small office
         electronic health record and practice management systems and converge
         its MyWay Electronic Health Record System and Professional Suite
         Electronic Health Record Systems.
       oA $16 million tax benefit reflecting the favorable settlement of an
         acquired tax position. In addition, a related $16 million write-off
         equal to the carrying value of the related tax indemnification asset,
         net of the settlement value is included in interest income and other
         within the consolidated statement of operations. Please refer to
         Settlement of Acquired Tax Position within the Explanation of
         Non-GAAP Financial Measures section in this press release for further
         discussion of these items.

  oNon-GAAP net income, after adjustments for certain non-cash and one-time
    items, was $39.4 million resulting in non-GAAP diluted earnings per share
    of $0.23. This compares with $45.2 million and $0.24, respectively, in
    the third quarter of 2011.
  oAllscripts forecasted annual effective tax rate on a non-GAAP basis
    decreased to approximately 29%. Accordingly, non-GAAP net income for the
    third quarter of 2012 reflects an adjustment to align with the new annual
    effective tax rate. The lower effective rate for 2012 results from a
    higher proportion of taxable income derived outside the United States
    which is taxed at lower rates plus an adjustment of a prior year research
    and development tax credit in the current quarter.

Please refer to Table 4 "Condensed Non-GAAP Financial Information" for a
complete reconciliation of all GAAP and non-GAAP financial measures discussed
in this press release.

"While market uncertainty impacted our sales in the third quarter, we are
pleased with our progress regarding important development initiatives" said
Glen Tullman, Chief Executive Officer of Allscripts. "There is significant
market interest in our Open platform, our advanced Mobility and Care
Coordination initiatives, and the upcoming release of Sunrise Financial
Manager, our new revenue cycle management solution. We are also investing
significantly to enhance the experience of our existing clients and lay the
foundation for long-term growth."

Liquidity and Cash Flow

During the third quarter of 2012, Allscripts repaid approximately $29.2
million of borrowings under its senior secured credit facilities. As of
September 30, 2012, the Company had $459.1 million of borrowings outstanding
and had approximately $249 million of available liquidity under its revolving
credit facility. The Company reported cash and marketable securities totaling
approximately $95.4 million on September 30, 2012.

For the three and nine months ended September 30, 2012, cash flow from
operations totaled $31.1 million and $164.5 million, respectively.

Company Evaluates Strategic Alternatives

Mr. Tullman continued, "We are confirming today that in light of the ongoing
interest expressed in the Company by third parties, the Company is evaluating
strategic alternatives. Regardless of the outcome of this process,
Allscripts' primary focus is and will continue to be serving our clients
through our industry-leading technology, services, and the support we provide
to 1,500 hospitals and over 50,000 ambulatory physician practices and
post-acute providers with whom we do business."

The Company further stated that there could be no assurance that this process
will result in any specific transaction. The Company does not intend to
comment further publicly with respect to the evaluation of strategic
alternatives unless a specific transaction is approved by its Board.
Citigroup is advising the Company.

Annual Guidance Commentary

The Company determined that, in light of the decision to evaluate strategic
alternatives, it is withdrawing its 2012 annual guidance.

Conference Call

Allscripts will conduct a conference call today, Thursday, November 8, 2012,
at 4:30 PM Eastern Time to discuss the Company's earnings and other
information. Investors can access the conference via the Internet at
http://investor.allscripts.com. Participants also may access the conference
call by dialing (877) 303-0543 (toll free in the US) or (973) 935-8787
(international) and requesting Conference ID #33030748.

A replay of the call will be available two hours after the conclusion of the
call, for a period of two weeks, at http://www.allscripts.com or by calling
(855) 859-2056 or (404) 537-3406 - Conference ID #33030748.

Supplemental and non-GAAP financial information is also available at
http://investor.allscripts.com.

Footnotes
(1) Bookings reflect the value of executed contracts for software, hardware,
    services, remote hosting, outsourcing and SaaS.

About Allscripts

Allscripts(NASDAQ:MDRX) delivers the insights that healthcare providers
require to generate world-class outcomes. The company's Electronic Health
Record, practice management and other clinical, revenue cycle, connectivity
and information solutions create aConnected Community of Health™ for
physicians, hospitals and post-acute organizations. To learn more about
Allscripts, please visitwww.allscripts.com, Twitter, YouTube and It Takes A
Community: The Allscripts Blog.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the federal securities laws. Statements regarding future events or
developments, our future performance, as well as management's expectations,
beliefs, intentions, plans, estimates or projections relating to the future
are forward-looking statements with the meaning of these laws. These
forward-looking statements are subject to a number of risks and uncertainties,
some of which are outlined below. As a result, no assurances can be given that
any of the events anticipated by the forward-looking statements will transpire
or occur, or if any of them do so, what impact they will have on our results
of operations or financial condition. Such risks, uncertainties and other
factors include, among other things: the possibility that the expected
synergies, efficiencies and cost savings of the merger with Eclipsys
Corporation ("Eclipsys") will not be realized, or will not be realized within
the expected time period; potential difficulties or delays in achieving
platform and product integration and the connection and movement of data among
hospitals, physicians, patients and others; the risk that the Allscripts and
Eclipsys businesses will not be integrated successfully; competition within
the industries in which we operate; failure to achieve certification under the
Health Information Technology for Economic and Clinical Health Act could
result in increased development costs, a breach of some customer obligations
and could put us at a competitive disadvantage in the marketplace; the volume
and timing of systems sales and installations, the impact of the realignment
of our sales and services organization; the possibility that our current
initiatives focused on product delivery, client experience and financial
performance may not be successful; the length of sales cycles and the
installation process and the possibility that our products will not achieve or
sustain market acceptance; the timing, cost and success or failure of new
product and service introductions, development and product upgrade releases;
competitive pressures including product offerings, pricing and promotional
activities; our ability to establish and maintain strategic relationships;
undetected errors or similar problems in our software products; the outcome of
any legal proceeding that has been or may be instituted against us; compliance
with existing laws, regulations and industry initiatives and future changes in
laws or regulations in the healthcare industry, including possible regulation
of our software by the U.S. Food and Drug Administration; the possibility of
product-related liabilities; our ability to attract and retain qualified
personnel; the implementation and speed of acceptance of the electronic record
provisions of the American Recovery and Reinvestment Act of 2009; maintaining
our intellectual property rights and litigation involving intellectual
property rights; risks related to third-party suppliers and our ability to
obtain, use or successfully integrate third-party licensed technology; we will
incur costs relating to the standardization of our small office electronic
health record and practice management systems that could adversely affect our
results of operations; breach of our security by third parties; and the
effects and results of the Company's evaluation of strategic alternatives are
uncertain. See our "Risk Factors" in Annual Report on Form 10-K for 2011 and
subsequent Quarterly Reports on Form 10-Q for a further discussion of these
and other risks and uncertainties applicable to our business. The statements
herein speak only as of their date and we undertake no duty to update any
forward-looking statement whether as a result of new information, future
events or changes in expectations.



Table 1
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)
                                                  September30,  December31,
                                                  2012           2011
ASSETS
Current assets:
Cash and cash equivalents                         $93.7          $157.8
Accounts receivable, net                          371.3          362.8
Deferred taxes, net                               40.6           40.6
Inventories                                       1.7            2.0
Prepaid expenses and other current assets         124.5          117.4
Total current assets                              631.8          680.6
Long-term marketable securities                   1.7            1.7
Fixed assets, net                                 143.8          122.6
Software development costs, net                   105.5          98.4
Intangible assets, net                            442.4          489.8
Goodwill                                          1,039.4        1,039.4
Deferred taxes, net                               5.0            5.0
Other assets                                      38.0           79.8
Total assets                                      $2,407.6       $2,517.3
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable                                  $51.8          $41.2
Accrued expenses                                  85.4           103.4
Accrued compensation and benefits                 29.2           31.8
Deferred revenue                                  301.1          288.9
Current maturities of long-term debt and capital  72.9           45.5
lease obligations
Total current liabilities                         540.4          510.8
Long-term debt                                    386.8          322.7
Deferred revenue                                  20.7           18.9
Deferred taxes, net                               122.3          119.7
Other liabilities                                 38.3           68.5
Total liabilities                                 1,108.5        1,040.6
Total stockholders' equity                        1,299.1        1,476.7
Total liabilities and stockholders' equity        $2,407.6       $2,517.3

Table 2
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(In millions, except per-share amounts)
(Unaudited)
                                        Three MonthsEnded  Nine MonthsEnded
                                        September 30,       September 30,
                                        2012       2011     2012      2011
Revenue:
System sales (a)                        $35.2      $54.6    $116.2    $165.4
Professional services                   62.7       65.3     201.6     179.0
Maintenance (a)                         119.3      113.2    354.3     325.4
Transaction processing and other        143.5      130.6    423.3     386.1
Total revenue                           360.7      363.7    1,095.4   1,055.9
Cost of revenue: (b)
System sales                            30.0       39.6     96.6      110.4
Professional services                   54.5       56.3     173.3     150.4
Maintenance                             36.6       32.8     108.9     101.0
Transaction processing and other        82.6       73.0     246.4     204.5
Total cost of revenue                   203.7      201.7    625.2     566.3
Gross profit                            157.0      162.0    470.2     489.6
Selling, general and administrative     90.4       92.2     280.0     297.8
expenses
Research and development                37.8       26.0     112.2     72.8
Asset impairment charges (c)            11.1       0.0      11.1      0.0
Amortization of intangible assets       8.5        9.4      27.0      28.1
Income from operations                  9.2        34.4     39.9      90.9
Interest expense                        (3.7)      (3.8)    (11.9)    (16.7)
Interest income and other (expense),    (15.9)     0.4      (15.3)    1.2
net (d)
(Loss) income before income taxes       (10.4)     31.0     12.7      75.4
Benefit (provision) for income taxes    19.8       (11.9)   10.5      (27.8)
(e)
Net income                              $9.4       $19.1    $23.2     $47.6
Earnings per share - basic and diluted  $0.05      $0.10    $0.13     $0.25
Weighted average common shares
outstanding:
Basic                                   170.9      188.3    181.2     189.1
Diluted                                 172.8      191.5    183.0     192.0
(a) Certain prior period amounts in
system sales have been reclassified to
maintenance to conform to the current   $0.0       $2.9     $6.3      $11.5
period presentation. The amount
reclassed for each period presented is
as follows:
(b) Includes pre-tax amortization of
intangibles for each period presented   $7.2       $7.2     $21.5     $21.8
as follows:
(c) Non-cash charge related to the
impairment of previously capitalized
sofware development costs for MyWay
including the net carrying value of a
perpetual license for certain software
code incorporated in MyWay.
(d) Interest income and other for the
three and nine months ended
September30, 2012 includes a $16
million pre-tax write-off of a tax
indemnification asset due to the
settlement of the acquired tax position
indemnified by Misys plc for an amount
less than the carrying value of the
indemnification asset. The write-off is
not deductible for tax purposes;
therefore, the tax effect of the
write-off partially offsets the tax
benefit discussed in note (e).
(e) The income tax benefit for the
three and nine months ended
September30, 2012 includes a $16
million tax benefit related to the
settlement of an acquired tax position
for an amount less than the carrying
value of the tax liability.

Table 3
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
                                        Three MonthsEnded  Nine MonthsEnded
                                        September 30,       September 30,
                                        2012       2011     2012      2011
Cash flows from operating activities:
Net income                              $9.4       $19.1    $23.2     $47.6
Non-cash adjustments to net income      50.6       56.7     149.2     149.6
Cash impact of changes in operating     (28.9)     (33.6)   (7.9)     (35.9)
assets and liabilities
Net cash provided by operating          31.1       42.2     164.5     161.3
activities
Cash flows from investing activities:
Capital expenditures                    (16.7)     (12.1)   (55.5)    (33.3)
Capitalized software                    (12.4)     (16.2)   (39.3)    (46.5)
Net (purchases) sales and maturities of
marketable securities and other         0.0        0.0      0.1       (12.8)
investments
Proceeds received from sale of fixed    0.0        0.0      0.0       20.0
assets
Change in restricted cash               0.0        0.0      0.0       2.2
Net cash used in investing activities   (29.1)     (28.3)   (94.7)    (70.4)
Cash flows from financing activities:
Proceeds from issuance of common stock  0.2        7.5      4.0       27.5
Excess tax benefits from stock-based    0.5        (2.4)    0.6       4.7
compensation
Taxes paid related to net share         (0.7)      (2.2)    (4.3)     (2.2)
settlement of equity awards
Debt borrowings (payments) net of       (29.6)     (46.0)   90.2      (114.3)
financing costs
Repurchase of common stock              0.0        0.0      (226.0)   (50.1)
Net cash used in financing activities   (29.6)     (43.1)   (135.5)   (134.4)
Effect of exchange rate changes on cash 0.9        (1.7)    1.6       (1.1)
and cash equivalents
Net decrease in cash and cash           (26.7)     (30.9)   (64.1)    (44.6)
equivalents
Cash and cash equivalents, beginning of 120.4      115.7    157.8     129.4
period
Cash and cash equivalents, end of       $93.7      $84.8    $93.7     $84.8
period

Table 4
Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)
                                  Three     Three     Nine Months  Nine Months
                                  Months    Months    Ended        Ended
                                  Ended     Ended
                                  9/30/12   9/30/11   9/30/12      9/30/11
Total revenue, as reported        $360.7    $363.7    $1,095.4     $1,055.9
 Deferred revenue adjustment  0.3       2.6       1.8          20.1
Total non-GAAP revenue            $361.0    $366.3    $1,097.2     $1,076.0
Gross profit, as reported         $157.0    $162.0    $470.2       $489.6
 Deferred revenue adjustment  0.3       2.6       1.8          20.1
Total non-GAAP gross profit       $157.3    $164.6    $472.0       $509.7
Operating income, as reported     $9.2      $34.4     $39.9        90.9
 Deferred revenue adjustment  0.3       2.6       1.8          20.1
 Acquisition-related          15.7      16.6      48.6         49.9
amortization
 Stock-based compensation     8.8       9.9       26.4         25.8
expense
 Transaction-related and      4.9       8.8       14.1         32.1
non-recurring expenses (a)
 Asset impairment charge (b)    11.1      0.0       11.1         0.0
Total non-GAAP operating income   $50.0     $72.3     $141.9       $218.8
Net income, as reported           $9.4      $19.1     $23.2        $47.6
 Deferred revenue adjustment 0.3       1.7       1.3          12.4
 Acquisition-related          13.3      11.0      34.0         31.3
amortization
 Stock-based compensation     7.5       6.5       18.6         16.2
expense
 Transaction-related and      4.1       5.8       9.9          21.1
non-recurring expenses (a)
 Asset impairment charge (b)   9.4       0.0       9.4          0.0
 Indemnification asset        13.6      0.0       13.6         0.0
write-off (c)
 Tax benefit (d)              (16.0)    0.0       (16.0)       0.0
 Tax rate alignment           (2.2)     1.1       (1.8)        (0.3)
Non-GAAP net income               $39.4     $45.2     $92.2        $128.3
Tax Rate                          15%       34%       29%          39%
Weighted shares outstanding -     172.8     191.5     183.0        192.0
diluted
Earnings per share - diluted, as  $0.05     $0.10     $0.13        $0.25
reported
Non-GAAP earnings per share -     $0.23     $0.24     $0.50        $0.67
diluted

Note: all adjustments to reconcile GAAP to non-GAAP net income
are net of tax
(a) Transaction-related expenses consist of integration expenses incurred in
connection with the Eclipsys Merger. Non-recurring expenses in the third
quarter of 2012 relate to certain legal, consulting and other fees incurred
in connection with activities that are considered one-time.
Transaction-related and non-recurring expenses, on a pretax basis, were
approximately $4.9 million in the quarter.
(b) Non-cash charge related to the impairment of previously capitalized
sofware development costs for MyWay including the net carrying value of a
perpetual license for certain software code incorporated in MyWay.
(c) Write-off of a tax indemnification asset due to the settlement of the
acquired tax position indemnified by Misys plc for an amount less than the
carrying value of the indemnification asset. The write-off is not deductible
for tax purposes.
(d) Tax benefit related to the settlement of an acquired tax position for an
amount less than the carrying value of the tax liability.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted
accounting principles, or GAAP. To supplement this information, Allscripts
presents in this release non-GAAP revenue, gross profit, operating income and
net income, including non-GAAP net income on a per share basis, which are
non-GAAP financial measures under Section 101 of Regulation G under the
Securities Exchange Act of 1934, as amended. Non-GAAP revenue consists of GAAP
revenue as reported and adds back the acquisition-related deferred revenue
adjustment booked for GAAP purposes. Non-GAAP gross profit consists of GAAP
gross profit as reported and adds back the acquisition-related deferred
revenue adjustment booked for GAAP purposes. Non-GAAP operating income
consists of GAAP operating income as reported and adds back the
acquisition-related deferred revenue adjustment booked for GAAP purposes and
excludes acquisition-related amortization, stock-based compensation expense,
transaction-related and non-recurring expenses. Non-GAAP net income consists
of GAAP net income as reported, excludes acquisition-related amortization,
stock-based compensation expense and transaction-related and non-recurring
expenses, and adds back the acquisition-related deferred revenue, in each case
net of any related tax effects. Non-GAAP net income also includes a tax rate
alignment adjustment.

Acquisition-Related Deferred Revenue. Acquisition-related deferred revenue
adjustment reflects the fair value adjustment to deferred revenues acquired in
business combinations. The fair value of deferred revenue represents an amount
equivalent to the estimated cost plus an appropriate profit margin, to perform
services related to the acquiree's software and product support, which assumes
a legal obligation to do so, based on the deferred revenue balances as of the
acquisition date. Allscripts adds back this deferred revenue for its non-GAAP
financial measures because it believes the inclusion of this amount directly
correlates to the underlying performance of Allscripts operations.

Acquisition-Related Amortization. Acquisition-related amortization expense is
a non-cash expense arising from the acquisition of intangible assets in
connection with acquisitions or investments. Allscripts excludes
acquisition-related amortization expense from non-GAAP operating income and
non-GAAP net income because it believes (i) the amount of such expenses in any
specific period may not directly correlate to the underlying performance of
Allscripts business operations and (ii) such expenses can vary significantly
between periods as a result of new acquisitions and full amortization of
previously acquired intangible assets. Investors should note that the use of
these intangible assets contributed to revenue in the periods presented and
will contribute to future revenue generation and the related amortization
expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a
non-cash expense arising from the grant of stock awards to employees.
Allscripts excludes stock-based compensation expense from non-GAAP operating
income and non-GAAP net income because it believes (i) the amount of such
expenses in any specific period may not directly correlate to the underlying
performance of Allscripts business operations and (ii) such expenses can vary
significantly between periods as a result of the timing of grants of new
stock-based awards, including grants in connection with acquisitions.
Investors should note that stock-based compensation is a key incentive offered
to employees whose efforts contributed to the operating results in the periods
presented and are expected to contribute to operating results in future
periods and such expense will recur in future periods.

Transaction-Related and Non-Recurring Expenses. Transaction-related expenses
are integration expenses incurred in connection with the Eclipsys Merger.
Allscripts excludes transaction-related expenses from non-GAAP operating
income and non-GAAP net income because it believes (i) the amount of such
expenses in any specific period may not directly correlate to the underlying
performance of Allscripts business operations and (ii) such expenses can vary
significantly between periods. Non-recurring expenses in the third quarter of
2012 include certain legal, consulting and other fees incurred in connection
with activities that are considered one-time.

Asset Impairment Charges. Allscripts announced on October 3, 2012, a plan to
standardize its small office electronic health record and practice management
systems. As part of this plan, Allscripts will converge, over time, its MyWay
Electronic Health Record System and Professional Suite Electronic Health
Record System. As a result, the Company recorded an $11.1 million non-cash
charge to earnings in the quarter ended September 30, 2012 related to the
impairment of previously capitalized software development costs for MyWay plus
the net carrying value of a perpetual license for certain software code
incorporated in MyWay.

Settlement of Acquired Tax Position. Pursuant to the Framework Agreement
between Misys plc and Allscripts signed in 2010, Misys agreed to indemnify
Allscripts against potential contingent tax liabilities for which it could be
potentially liable, arising from Allscripts' purchase of Allscripts shares
from Misys plc in 2010. During the three months ended September 30, 2012,
Allscripts settled the acquired tax position indemnified by Misys plc for an
amount less than the carrying value of the unrecognized tax liability totaling
$29 million. Accordingly, the result for GAAP purposes was the write-off of
the remaining tax indemnification asset totaling $16 million, on a pre-tax
basis. This charge is substantially not deductible for tax purposes. In
addition, the Company decreased its unrecognized tax liability and recorded an
offsetting tax benefit of $16 million for the three months ended September 30,
2012. More details on this topic are available on Forms S-4, 10-K and 10-Q
filed with the Securities and Exchange Commission on June 29, 2010, February
29, 2012 and August 9, 2012, respectively, as well as other Company filings.

Tax Rate Alignment. Tax adjustment to align the current quarter's effective
tax rate to the expected annual effective tax rate.

Management also believes that non-GAAP revenue, gross profit, operating income
and net income and non-GAAP net income on a per share basis provide useful
supplemental information to management and investors regarding the underlying
performance of the Company's business operations. Acquisition accounting
adjustments made in accordance with GAAP can make it difficult to make
meaningful comparisons of the underlying operations of the business without
considering the non-GAAP adjustments that we have provided and discussed
herein. Management also uses this information internally for forecasting and
budgeting as it believes that these measures are indicative of the Company's
core operating results. In addition, the Company uses non-GAAP revenue,
operating income and/or net income to measure achievement under the Company's
stock and cash incentive compensation plans. Note, however, that non-GAAP
revenue, gross profit, operating income and net income and non-GAAP net income
on a per share basis are performance measures only, and they do not provide
any measure of the Company's cash flow or liquidity. Non-GAAP financial
measures are not in accordance with, or an alternative for, measures of
financial performance prepared in accordance with GAAP and may be different
from non-GAAP measures used by other companies. Non-GAAP measures have
limitations in that they do not reflect all of the amounts associated with
Allscripts results of operations as determined in accordance with GAAP.
Investors and potential investors are encouraged to review the reconciliation
of non-GAAP financial measures with GAAP financial measures contained within
the attached condensed consolidated financial statements.

(Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO)

SOURCE Allscripts Healthcare Solutions, Inc.

Website: http://www.allscripts.com
Contact: Investors, Seth Frank, +1-312-506-1213, seth.frank@allscripts.com, or
Media, Ariana Nikitas, +1-312-506-1236, ariana.nikitas@allscripts.com
 
Press spacebar to pause and continue. Press esc to stop.